ArticleNature protocols2014
Antibiotic resistance-mediated isolation of scaffold-specific natural product producers.
Article in Nature protocols, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Exploring northeast India's culturable soil Actinomycetia for potent antibacterial agents against gram-positive bacterial pathogens of clinical importance.Scientific reports · 2024Article
- Harnessing Gram-negative bacteria for novel anti-Gram-negative antibiotics.Microbial biotechnology · 2024Review
- Draft genome sequence ofMicrobiology resource announcements · 2023Article
- Draft Genome Sequence ofMicrobiology resource announcements · 2023Article
- High-Throughput Screening of Natural Product and Synthetic Molecule Libraries for Antibacterial Drug Discovery.Metabolites · 2023Review
- Strategies to access biosynthetic novelty in bacterial genomes for drug discovery.Nature reviews. Drug discovery · 2022Review
- Genome mining for drug discovery: progress at the front end.Journal of industrial microbiology & biotechnology · 2021Review
- Exiguobacterium sp. is endowed with antibiotic properties against Gram positive and negative bacteria.BMC research notes · 2021Article
- Resistance-guided isolation and characterization of antibiotic-producing bacteria from river sediments.BMC microbiology · 2021Article
- The need to innovate sample collection and library generation in microbial drug discovery: a focus on academia.Natural product reports · 2021Article
- Selective Isolation of Multidrug-ResistantFrontiers in microbiology · 2021Article
- Computational Tools for Discovering and Engineering Natural Product Biosynthetic Pathways.iScience · 2020Review
- Engineering enzymatic assembly lines to produce new antibiotics.Current opinion in microbiology · 2019Review
- Detecting and prioritizing biosynthetic gene clusters for bioactive compounds in bacteria and fungi.Applied microbiology and biotechnology · 2019Review
- Antitumor Anthraquinones from an Easter Island Sea Anemone: Animal or Bacterial Origin?Marine drugs · 2019Article
- Extracellularly oxidative activation and inactivation of matured prodrug for cryptic self-resistance in naphthyridinomycin biosynthesis.Proceedings of the National Academy of Sciences of the United States of America · 2018Article
- Developments in Glycopeptide Antibiotics.ACS infectious diseases · 2018Article
- Current Status and Future Prospects of Marine Natural Products (MNPs) as Antimicrobials.Marine drugs · 2017Review
- The Antibiotic Resistant Target Seeker (ARTS), an exploration engine for antibiotic cluster prioritization and novel drug target discovery.Nucleic acids research · 2017Article
- Gifted microbes for genome mining and natural product discovery.Journal of industrial microbiology & biotechnology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
For over half a century, actinomycetes have served as the most promising source of novel antibacterial scaffolds. However, over the years, there has been a decline in the discovery of new antibiotics from actinomycetes. This is partly due to the use of standard screening methods and platforms that result in the re-discovery of the same molecules. Thus, according to current estimates, the discovery of a new antibacterial requires screening of tens to hundreds of thousands of bacterial strains. We have devised a resistance-based antibacterial discovery platform by harnessing the innate self-protection mechanism of antibiotic producers. This protocol provides a detailed method for isolation of scaffold-specific antibacterial producers by isolating strains in the presence of a selective antibiotic. As a specific example, we describe isolation of glycopeptide antibiotic (GPA) producers from soil actinomycetes, using vancomycin as the antibiotic resistance filter. However, the protocol can be adapted to isolate diverse producers from various sources producing different scaffolds, by selecting an appropriate antibiotic as a screening filter. The protocol provides a solution for two major bottlenecks that impede the new drug discovery pipeline: low hit frequency and re-discovery of known molecules. The entire protocol, from soil collection to identification of putative antibacterial producers, takes about 6 weeks to complete.
Indexed as
Identifiers
24874813What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.